

IMAGE



Infographic: Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy (PDR): DRCR.net Protocol S

Imran H. Yusuf^{1,2✉}, Christin Henein^{3,4} and Sobha Sivaprasad^{1,4}


© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2023

Eye (2024) 38:37–38; https://doi.org/10.1038/s41433-023-02396-0

This DRCR.net Protocol S trial sought to determine whether ranibizumab was non-inferior (<5 ETDRS letters) to PRP for visual acuity outcomes in patients with proliferative diabetic retinopathy. Patients were excluded if previous PRP, neovascularisation of the angle, end-stage renal failure, or systemic vascular event within 4 months of randomization. 89 patients had both eyes enrolled; one to each study group. PRP was applied over 1–3 visits, with additional PRP for increased neovascularisation. In the other treatment group, Ranibizumab was given at baseline, and as often as every 4 weeks

based on pre-defined criteria and until all neovascularisation had resolved. Both groups could receive ranibizumab for DME (vision <20/32 with central retinal thickening on optical coherence tomography imaging). One eye in the ranibizumab group developed endophthalmitis.

PDR – proliferative diabetic retinopathy; DRCR – Diabetic Retinopathy Clinical Research Network; DM – diabetes mellitus; ETDRS – Early Treatment Diabetic Retinopathy Study; DME – diabetic macular oedema; CI – confidence interval; dB – decibels.



¹Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, Oxford University, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK. ²Oxford Eye Hospital, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford OX3 9DU, UK. ³UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK. ⁴NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. ✉email: Imran.yusuf@eye.ox.ac.uk

Received: 6 December 2022 Revised: 10 December 2022 Accepted: 13 January 2023
Published online: 21 April 2023

Reference: Writing Committee for the Diabetic Retinopathy Clinical Research Network. "Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy: a Randomized Clinical Trial" JAMA, 2015. 2015;314:2137–2146.

FUNDING

Medical Research Council UK (MR/R000735/1).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Imran H. Yusuf.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Please note that the infographic is best viewed online.